Konakion MM Paediatric approved for intramuscular use

Konakion MM Paediatric (phytomenadione 2mg per 0.2ml) has been approved for intramuscular administration for the treatment of vitamin K deficiency bleeding in healthy neonates of 36 weeks gestation and older.

Previously, Konakion MM Paediatric was licensed only for oral administration. Approval for intramuscular use of the product follows the discontinuation of Konakion Neonatal (phytomenadione 1mg per 0.5ml).

Health professionals are advised to exercise caution to avoid dosage errors with Konakion MM Paediatric as it is five times stronger than Konakion Neonatal.

The recommended dose for healthy neonates of 36 weeks gestation or older is 0.1ml (1mg) by intramuscular injection at or shortly after birth and NOT 0.5 ml as previously used for the neonatal formulation.

Further information: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Herts AL7 1TW. Tel: (01707) 366000.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in